title: Acute pain management in opioid-tolerant patients: a growing challenge.
abstract: In Australia and New Zealand, in parallel with other developed countries, the number of patients prescribed opioids on a long-term basis has grown rapidly over the last decade. The burden of chronic pain is more widely recognised and there has been an increase in the use of opioids for both cancer and non-cancer indications. While the prevalence of illicit opioid use has remained relatively stable, the diversion and abuse of prescription opioids has escalated, as has the number of individuals receiving methadone or buprenorphine pharmacotherapy for opioid addiction. As a result, the proportion of opioid-tolerant patients requiring acute pain management has increased, often presenting clinicians with greater challenges than those faced when treating the opioid-naïve. Treatment aims include effective relief of acute pain, prevention of drug withdrawal, assistance with any related social, psychiatric and behavioural issues, and ensuring continuity of long-term care. Pharmacological approaches incorporate the continuation of usual medications (or equivalent), short-term use of sometimes much higher than average doses of additional opioid, and prescription of non-opioid and adjuvant drugs, aiming to improve pain relief and attenuate opioid tolerance and/or opioid-induced hyperalgesia. Discharge planning should commence at an early stage and may involve the use of a 'Reverse Pain Ladder' aiming to limit duration of additional opioid use. Legislative requirements may restrict which drugs can be prescribed at the time of hospital discharge. At all stages, there should be appropriate and regular consultation and liaison with the patient, other treating teams and specialist services.
authors.affiliation: Department of Anaesthesia, Pain Medicine and Hyperbaric Medicine, Royal Adelaide Hospital, Adelaide, South Australia christine.huxtable@health.sa.gov.au
authors.forename: C A
authors.initials: CA
authors.lastname: Huxtable
authors.forename: L J
authors.initials: LJ
authors.lastname: Roberts
authors.forename: A A
authors.initials: AA
authors.lastname: Somogyi
authors.forename: P E
authors.initials: PE
authors.lastname: MacIntyre
mesh_terms: D000208:Acute Disease; D000700:Analgesics / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000818:Animals; D001315:Australia; D002047:Buprenorphine; D000069479:Buprenorphine, Naloxone Drug Combination; D004361:Drug Tolerance; D006801:Humans; D006930:Hyperalgesia / Q000139:chemically induced; D013287:Illicit Drugs; D008691:Methadone; D009270:Naloxone; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009294:Narcotics; D009520:New Zealand; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000150:complications*; D010146:Pain / Q000150:complications* / Q000188:drug therapy*; D010149:Postoperative Pain / Q000188:drug therapy; D010351:Patient Discharge; D011300:Preoperative Care / Q000379:methods; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid; D000069479:Buprenorphine, Naloxone Drug Combination; D013287:Illicit Drugs; D009292:Narcotic Antagonists; D009294:Narcotics; D009270:Naloxone; D002047:Buprenorphine; D008691:Methadone